Genitourinary Syndrome of Menopause

Key points

• Genitourinary syndrome is a complex chronic syndrome with multiple changes in genitourinary tissues in response to menopausal loss of estrogen.

• Symptoms range from mild to severe and may have effects on genitourinary and sexual function, relationships and quality of life.

• Treatments can be non-hormonal with lubricants and moisturizers or with vaginal or systemic estrogen therapy.

• A multidisciplinary approach may be needed when there are complex problems, including sexual dysfunction.

• The gynecologist is in a unique position to sensitively discuss the symptoms of genitourinary syndrome, advise, educate and treat appropriately, providing long-term follow-up.

The National Specialty Commission on Climateric of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.

Publikationsverlauf

Artikel online veröffentlicht:
16. Mai 2022

• References

• 1 Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21 (10) 1063-8
• 2 Cagnacci A, Xholli A, Sclauzero M, Venier M, Palma F, Gambacciani M. et al. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric 2019; 22 (01) 85-9
• 3 Nappi RE, de Melo NR, Martino M, Celis-González C, Villaseca P, Röhrich S. et al. Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America. Climacteric 2018; 21 (04) 397-403
• 4 The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 2020; 27 (09) 976-92
• 5 Frank SM, Ziegler C, Kokot-Kierepa M, Maamari R, Nappi RE. Vaginal Health: Insights, Views & Attitudes (VIVA) survey – Canadian cohort. Menopause Int 2013; 19 (01) 20-7
• 6 Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013; 10 (07) 1790-9
• 7 Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?. Climacteric 2016; 19 (02) 151-61
• 8 Potter N, Panay N. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Climacteric 2021; 24 (01) 19-24
• 9 Dos Santos CC, Uggioni ML, Colonetti T, Colonetti L, Grande AJ, Da Rosa MI. Hyaluronic acid in postmenopause vaginal atrophy: a systematic review. J Sex Med 2021; 18 (01) 156-66
• 10 Baber RJ, Panay N, Fenton A. IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016; 19 (02) 109-50
• 11 Donders GG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother 2019; 20 (07) 821-35
• 12 Nachtigall L, Lang E, Gut R, Utian W, Archer DF, Simon J. An ultra-low dose (10μg) estradiol vaginal tablet improves signs and symptoms associated with vaginal atrophy. Fertil Steril 2008; 90 Suppl: S250
• 13 Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M. VAG-1748 trial investigators. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 2010; 13 (03) 228-37
• 14 Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010; 116 (04) 876-83
• 15 Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric 2010; 13 (03) 219-27
• 16 Pompei LM, Fernandes CE, Melo NR. Promestrieno no tratamento da atrofia vulvovaginal: revisão sistemática. Femina 2010; 38 (07) 359-65
• 17 Sun AJ, Lin SQ, Jing LH, Wang ZY, Ye JL, Zhang Y. [Safety of promestriene capsule used in postmenopausal atrophic vaginitis]. Zhonghua Fu Chan Ke Za Zhi 2009; 44 (08) 593-6 . Chinese
• 18 Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P. et al. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?. Anticancer Drugs 2013; 24 (10) 989-98
• 19 Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause 2019; 26 (04) 431-53
• 20 Wańczyk-Baszak J, Woźniak S, Milejski B, Paszkowski T. Genitourinary syndrome of menopause treatment using lasers and temperature-controlled radiofrequency. Prz Menopauzalny 2018; 17 (04) 180-4
• 21 Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A. et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med 2017; 49 (02) 137-59
• 22 Sarmento AC, Lírio JF, Medeiros KS, Marconi C, Costa AP, Crispim JC. et al. Physical methods for the treatment of genitourinary syndrome of menopause: a systematic review. Int J Gynaecol Obstet 2021; 153 (02) 200-19
• 23 Knight C, Logan V, Fenlon D. A systematic review of laser therapy for vulvovaginal atrophy/genitourinary syndrome of menopause in breast cancer survivors. Ecancermedicalscience 2019; 13: 988
• 24 Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV. et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014; 124 (06) 1147-56
• 25 Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; 10: CD001405
• 26 Bachmann G, Santen RJ. Genitourinary syndrome of menopause (vulvovaginal atrophy): treatment [Internet]. 2021 [cited 2021 Oct 30]. Available from: https://www.uptodate.com/contents/genitourinary-syndrome-of-menopause-vulvovaginal-atrophy-treatment
• 27 Vesna A, Neli B. Benefit and safety of 28-day transdermal estrogen regimen during vaginal hysterectomy (a controlled trial). Maturitas 2006; 53 (03) 282-98
• 28 ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016; 127 (03) e93-6
• 29 Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018; 25 (06) 596-608
• 30 American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice. Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer [Internet]. 2016 (Reaffirmed 2020) [cited 2021 Oct 30]. Available from: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2016/03/the-use-of-vaginal-estrogen-in-women-with-a-history-of-estrogen-dependent-breast-cancer